Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 131.25 $ 0.48 (0.37 %)    

Friday, 26-Apr-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 131.2
$ 130.66
$ 0.00 x 0
$ 0.00 x 0
$ 130.14 - $ 131.91
$ 97.81 - $ 133.10
7,758,230
na
nm
$ 0.33
nm
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-26-2024 12-31-2023 10-K
2 11-03-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-05-2023 03-31-2023 10-Q
5 02-24-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-25-2022 12-31-2021 10-K
10 11-05-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-05-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 02-26-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 02-27-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 02-27-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 02-28-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 02-26-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-06-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 02-27-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

truist-securities-maintains-buy-on-merck--co-raises-price-target-to-143
Truist Securities Maintains Buy on Merck &...
04/26/2024 15:52:17

Truist Securities analyst Robyn Karnauskas maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $...

investor-sentiment-improves-slightly-but-dow-tumbles-over-350-points
Investor Sentiment Improves Slightly, But ...
04/26/2024 06:59:07

stocks-drop-tech-tumbles-with-metas-weak-outlook-q1-stagflation-fears-gold-miners-advance-whats-driving-markets-thursday
Stocks Drop, Tech Tumbles With Meta's Weak...
04/25/2024 17:30:32

Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NA...

merck-stock-gains-on-its-blockbuster-cancer-drug-keytruda-raises-annual-outlook
Merck Stock Gains On Its Blockbuster Cance...
04/25/2024 16:29:01

Merck reported Q1 sales of $15.8 billion, beating estimates, with cancer drug Keytruda driving growth. Company raised full-year...

sp-500-down-over-1-merck-increases-2024-outlook
S&P 500 Down Over 1%; Merck Increases 2024...
04/25/2024 16:04:30

meta-falls-15-on-great-earnings-tesla-rises-12-on-ugly-earnings--here-is-the-real-reason
Meta Falls 15% On Great Earnings, Tesla Ri...
04/25/2024 14:51:25

To gain an edge, this is what you need to know today.

merck-forecasts-2024-adjusted-eps-of-853-865-versus-prior-guidance-of-844-859-and-consensus-of-856
Merck Forecasts 2024 Adjusted EPS Of $8.53...
04/25/2024 10:34:43

merck-forecasts-2024-sales-guidance-of-631b-643b-versus-prior-guidance-of-627b-642b-and-consensus-of-6382b
Merck Forecasts 2024 Sales Guidance Of $63...
04/25/2024 10:33:21

merck--co-q1-2024-adj-eps-207-beats-188-estimate-sales-15775b-beat-15196b-estimate
Merck & Co Q1 2024 Adj EPS $2.07 Beats $1....
04/25/2024 10:31:39

Merck & Co (NYSE:MRK) reported quarterly earnings of $2.07 per share which beat the analyst consensus estimate of $1.88 by ...

us-stocks-brace-for-negative-start-amid-tech-earnings-disappointments-caution-ahead-of-data-worst-of-this-two-week-decline-is-behind-us-says-analyst
US Stocks Brace For Negative Start Amid Te...
04/25/2024 10:17:18

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platfor...

why-australian-cancer-biotech-firm-immutep-stock-is-soaring-on-wednesday
Why Australian Cancer Biotech Firm Immutep...
04/24/2024 14:43:20

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients...

understanding-merck-amp-cos-position-in-pharmaceuticals-industry-compared-to-competitors
Understanding Merck & Co's Position In...
04/23/2024 15:00:49

looking-into-merck--cos-recent-short-interest
Looking Into Merck & Co's Recent Short Int...
04/23/2024 13:45:26

can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsoft-meta-alphabet-and-tesla-expected-this-week
Can Magnificent 7 Help Script Market Turna...
04/21/2024 21:45:15

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

merck-says-health-canada-approved-keytruda-combination-as-first-line-treatment-for-adult-patients-with-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gej-adenocarcinoma
Merck Says Health Canada Approved KEYTRUDA...
04/19/2024 11:07:29

unveiling-17-analyst-insights-on-merck--co
Unveiling 17 Analyst Insights On Merck & Co
04/18/2024 18:01:14

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-135-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/18/2024 13:58:35

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $135 price target.

market-whales-and-their-recent-bets-on-mrk-options
Market Whales and Their Recent Bets on MRK...
04/17/2024 20:15:54

declining-covid-19-vaccine-sales-pinches-moderna-pauses-kenya-vaccine-plant-plans
Declining COVID-19 Vaccine Sales Pinches M...
04/11/2024 15:24:17

Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders p...

vaccine-player-vaxcyte-has-advantage-over-pfizer-mercks-pneumococcal-shots---analyst-says
Vaccine Player Vaxcyte Has Advantage Over ...
04/10/2024 18:42:39

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION